Aberrant striatal synaptic plasticity in monogenic parkinsonisms

Neuroscience

Volumn 211, Issue , 2012, Pages 126-135

  Madeo, G ^a   Martella, G ^a   Schirinzi, T ^a   Ponterio, G ^a,b   Shen, J ^c   Bonsi, P ^b   Pisani, A ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Animal model; Parkinson's disease; Striatum; Synaptic plasticity

Indexed keywords

DOPAMINE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE; PTEN INDUCED KINASE1; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BEHAVIOR DISORDER; CORPUS STRIATUM; DISEASE ACTIVITY; DISEASE COURSE; DJ 1 GENE; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; GENE; GENE MUTATION; GENE REARRANGEMENT; HETEROZYGOTE; HOMEOSTASIS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; LRRK2 GENE; MONOGENIC DISORDER; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPHYSIOLOGY; NONHUMAN; PARKIN GENE; PARKINSONISM; PATHOGENESIS; PINK1 GENE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HOMEOSTASIS; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; NEURONAL PLASTICITY; PARKINSONIAN DISORDERS; SYNAPTIC TRANSMISSION;

EID: 84860617691     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.07.065     Document Type: Review

References (88)

1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25(1):239-252.
2. Abou-Sleiman P.M., Muqit M.M., McDonald N.Q., Yang Y.X., Gandhi S., Healy D.G., Harvey K., Harvey R.J., Deas E., Bhatia K., Quin N., Lees A., Latchman D.S., Wood N.W. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 2006, 60:414-419.
3. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
4. Bäumer T., Pramstaller P.P., Siebner H.R., Schippling S., Hagenah J., Peller M., Gerloff C., Klein C., Münchau A. Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: a TMS study. Neurology 2007, 69:1976-1981.
5. Bonifati V., Rizzu P., Squitieri F., Krieger E., Vanacore N., van Swieten J.C., Brice A., van Duijn C.M., Oostra B., Meco G., Heutink P. DJ-1(PARK7), a novel gene for autosomal recessive, early onset Parkinsonism. Neurol Sci 2003, 24:159-160.
6. Buhmann C., Binkofski F., Klein C., Büchel C., van Eimeren T., Erdmann C., Hedrich K., Kasten M., Hagenah J., Deuschl G., Pramstaller P.P., Siebner H.R. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic Parkinsonism. Brain 2005, 128:2281-2290.
7. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Südhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
8. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993, 116(Pt 2):433-452.
9. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
10. Centonze D., Picconi B., Gubellini P., Bernardi G., Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 2001, 13:1071-1077.
11. Cheng F, Vivacqua G, Shun Y (in press) The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat, in press.
12. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink 1 is required for mitochondrial function and interacts genetically with Parkin. Nature 2006, 441:1162-1166.
13. Cookson M.R. Pathways to Parkinsonism. Neuron 2003, 37:7-10.
14. Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010, 11:791-797.
15. Cookson M.R., Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet 2010, 19:R21-R27.
16. Cookson M.R., Dauer W., Dawson T., Fon E.A., Guo M., Shen J. The roles of kinases in familial Parkinson's disease. J Neurosci 2007, 27:11865-11868.
17. Darios F., Ruipérez V., López I., Villanueva J., Gutierrez L.M., Davletov B. Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep 2010, 11:528-533.
18. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
19. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
20. De Rosa A., Volpe G., Marcantonio L., Santoro L., Brice A., Filla A., Perretti A., De Michele G. Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations. J Neurol 2006, 253:275-279.
21. Deas E., Plun-Favreau H., Wood N.W. PINK1 function in health and disease. EMBO Mol Med 2009, 1:152-165.
22. Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., Cookson M.R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008, 105(5):1499-1504.
23. Eggers C., Schmidt A., Hagenah J., Brüggemann N., Klein J.C., Tadic V., Kertelge L., Kasten M., Binkofski F., Siebner H., Neumaier B., Fink G.R., Hilker R., Klein C. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010, 74:1798-1805.
24. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., Hartley M., Treviño I., O'Brien D.E., Casey B., Goldberg M.S., Tansey M.G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28:10825-10834.
25. Gasser T. Update on the genetics of Parkinson's disease. Mov Disord 2007, 22(Suppl 17):S343-S350.
26. Geisler S., Holmström K.M., Treis A., Skujat D., Weber S.S., Fiesel F.C., Kahle P.J., Springer W. The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations. Autophagy 2010, 6:871-878.
27. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003, 278(44):43628-43635.
28. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
29. Gureviciene I., Gurevicius K., Tanila H. Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus. J Neural Transm 2009, 116(1):13-22.
30. Hedrich K., Eskelson C., Wilmot B., Marder K., Harris J., Garrels J., Meija-Santana H., Vieregge P., Jacobs H., Bressman S.B., Lang A.E., Kann M., Abbruzzese G., Martinelli P., Schwinger E., Ozelius L.J., Pramstaller P.P., Klein C., Kramer P. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 2004, 19:1146-1157.
31. Hilker R., Klein C., Ghaemi M., Kis B., Strotmann T., Ozelius L.J., Lenz O., Vieregge P., Herholz K., Heiss W.D., Pramstaller P.P. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the Parkin gene. Ann Neurol 2001, 49:367-376.
32. Hu M.T., Scherfler C., Khan N.L., Hajnal J.V., Lees A.J., Quinn N., Wood N.W., Brooks D.J. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Mov Disord 2006, 21:299-305.
33. Khan N.L., Brooks D.J., Pavese N., Sweeney M.G., Wood N.W., Lees A.J., Piccini P. Progression of nigrostriatal dysfunction in a Parkin kindred: an [18F]dopa PET and clinical study. Brain 2002, 125:2248-2256.
34. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutation in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
35. Kim Y., Park J., Kim S., Song S., Kwon S.K., Lee S.H., Kitada T., Kim J.M., Chung J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 2008, 377:975-980.
36. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 1998, 392:605-608.
37. Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscherter A., Platania P., Wu B., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of Parkin-/-mice. J Neurochem 2009, 110:613-621.
38. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 2007, 104:11441-11446.
39. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher M.G., Lang A.E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007, 6:652-662.
40. Krebiehl G., Ruckerbauer S., Burbulla L.F., Kieper N., Maurer B., Waak J., Wolburg H., Gizatullina Z., Gellerich F.N., Woitalla D., Riess O., Kahle P.J., Proikas-Cezanne T., Krüger R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS ONE 2010, 5:e9367.
41. Kurz A., Double K.L., Lastres-Becker I., Tozzi A., Tantucci M., Bockhart V., Bonin M., García-Arencibia M., Nuber S., Schlaudraff F., Liss B., Fernández-Ruiz J., Gerlach M., Wüllner U., Lüddens H., Calabresi P., Auburger G., Gispert S. A53T-alpha-synuclein over expression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS ONE 2010, 5(7):e11464.
42. Lacey M.G., Mercuri N.B., North R.A. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol 1987, 392:397-416.
43. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010, 30(5):1788-1797.
44. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12(7):826-828.
45. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., Chen Z.Z., Gallant P.E., Tao-Cheng J.H., Rudow G., Troncoso J.C., Liu Z., Li Z., Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64(6):807-827.
46. Lohmann E., Periquet M., Bonifati V., Wood N.W., De Michele G., Bonnet A.M., Fraix V., Broussolle E., Horstink M.W., Vidailhet M., Verpillat P., Gasser T., Nicholl D., Teive H., Raskin S., Rascol O., Destée A., Ruberg M., Gasparini F., Meco G., Agid Y., Durr A., Brice A. How much phenotypic variation can be attributed to Parkin genotype?. Ann Neurol 2003, 54:176-185.
47. Lovinger D.M. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010, 58:951-961.
48. Martella G., Platania P., Vita D., Sciamanna G., Cuomo D., Tassone A., Tscherter A., Kitada T., Bonsi P., Shen J., Pisani A. Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial Parkinsonism-linked genes PINK1 or Parkin. Exp Neurol 2009, 215:388-396.
49. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 2000, 275:8812-8816.
50. Melrose H.L., Dächsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., Kent C.B., Korvatska E., Taylor J.P., Witten L., Liang Y.Q., Beevers J.E., Boules M., Dugger B.N., Serna V.A., Gaukhman A., Yu X., Castanedes-Casey M., Braithwaite A.T., Ogholikhan S., Yu N., Bass D., Tyndall G., Schellenberg G.D., Dickson D.W., Janus C., Farrer M.J. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010, 40(3):503-517.
51. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997, 79:323-327.
52. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88:1-16.
53. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., Ruth T.J., Strongosky A., Farrer M.J., Wszolek Z.K., Stoessl A.J. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71:1790-1795.
54. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., Lanciego J.L., Artieda J., Gonzalo N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000, 23:S8-S19.
55. Obi T., Nishioka K., Ross O.A., Terada T., Yamazaki K., Sugiura A., Takanashi M., Mizoguchi K., Mori H., Mizuno Y., Hattori N. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 2008, 70:238-241.
56. Paisán-Ruíz C., Jain S., Evans E.W., Gilks W.P., Simón J., van der Brug M., López de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Martí-Massó J.F., Pérez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
57. Park J., Lee G., Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun 2009, 378:518-523.
58. Piccini P., Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol 2004, 3:284-290.
59. Picconi B., Pisani A., Centonze D., Battaglia G., Storto M., Nicoletti F., Bernardi G., Calabresi P. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 2002, 125:2635-2645.
60. Pisani A., Centonze D., Bernardi G., Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 2005, 20:395-402.
61. Pisani V., Madeo G., Tassone A., Sciamanna G., Maccarrone M., Stanzione P., Pisani A. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord 2011, 26:216-222.
62. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
63. Ross O.A., Braithwaite A.T., Skipper L.M., Kachergus J., Hulihan M.M., Middleton F.A., Nishioka K., Fuchs J., Gasser T., Maraganore D.M., Adler C.H., Larvor L., Chartier-Harlin M.C., Nilsson C., Langston J.W., Gwinn K., Hattori N., Farrer M.J. Genomic investigation of alpha-synuclein multiplication and Parkinsonism. Ann Neurol 2008, 63:743-750.
64. Schiesling C., Kieper N., Seidel K., Krüger R. Familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 2008, 34:255-271.
65. Schneider S.A., Talelli P., Cheeran B.J., Khan N.L., Wood N.W., Rothwell J.C., Bhatia K.P. Motor cortical physiology in patients and asymptomatic carriers of Parkin gene mutations. Mov Disord 2008, 23:1812-1819.
66. Shen J., Cookson M.R. Mitochondria and dopamine: new insights into recessive Parkinsonism. Neuron 2004, 43:301-304.
67. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, Parkin, is a ubiquitin-protein ligase. Nat Genet 2000, 25:302-305.
68. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
69. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., Nicholson G.A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001, 49:313-319.
70. Steidl J.V., Gomez-Isla T., Mariash A., Ashe K.H., Boland L.M. Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice. Neuroreport 2003, 14(2):219-223.
71. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009, 106(34):14622-14627.
72. Tong Y., Shen J. Alpha-synuclein and LRRK2: partners in crime. Neuron 2009, 64(6):771-773.
73. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 2010, 107(21):9879-9884.
74. Tozzi A, Costa C, Siliquini S, Tantucci M, Picconi B, Kurz A, Gispert S, Auburger G, Calabresi P (in press) Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiol Aging.
75. Unoki M., Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001, 20:4457-4465.
76. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., González-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
77. Valente E.M., Brancati F., Ferraris A., Graham E.A., Davis M.B., Breteler M.M., Gasser T., Bonifati V., Bentivoglio A.R., De Michele G., Dürr A., Cortelli P., Wassilowsky D., Harhangi B.S., Rawal N., Caputo V., Filla A., Meco G., Oostra B.A., Brice A., Albanese A., Dallapiccola B., Wood N.W. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002, 51:14-18.
78. van der Vegt J.P., van Nuenen B.F., Bloem B.R., Klein C., Siebner H.R. Imaging the impact of genes on Parkinson's disease. Neuroscience 2009, 164:191-204.
79. van Nuenen B.F., van Eimeren T., van der Vegt J.P., Buhmann C., Klein C., Bloem B.R., Siebner H.R. Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov Disord 2009, 24(Suppl 2):S703-S710.
80. Varrone A., Pellecchia M.T., Amboni M., Sansone V., Salvatore E., Ghezzi D., Garavaglia B., Brice A., Brunetti A., Bonavita V., De Michele G., Salvatore M., Pappatà S., Barone P. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset Parkin disease. Neurology 2004, 63:2097-2103.
81. Vekrellis K., Rideout H.J., Stefanis L. Neurobiology of alpha-synuclein. Mol Neurobiol 2004, 30:1-21.
82. Watson J.B., Hatami A., David H., Masliah E., Roberts K., Evans C.E., Levine M.S. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009, 159(2):501-513.
83. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005, 102:16842-16847.
84. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007, 16:223-232.
85. Xiong H., Wang D., Chen L., Choo Y.S., Ma H., Tang C., Xia K., Jiang W., Ronai Z., Zhuang X., Zhang Z. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009, 119:650-660.
86. Yang Y., Gehrk S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 2006, 103:10793-10798.
87. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.
88. Zimprich A., Müller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M., Lockhart P., Strongosky A., Kachergus J., Calne D.B., Stoessl J., Uitti R.J., Pfeiffer R.F., Trenkwalder C., Homann N., Ott E., Wenzel K., Asmus F., Hardy J., Wszolek Z., Gasser T. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004, 74:11-19.